Howe & Rusling’s Humacyte HUMA Stock Holding History

Howe & Rusling’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-200	Closed	-$1K	–	1107
2022 Q1	$1K	Hold	200	–	–	﹤0.01%	932
2021 Q4	$1K	Hold	200	–	–	﹤0.01%	929
2021 Q3	$2K	Hold	200	–	–	﹤0.01%	850
2021 Q2	$2K	Buy	+200	New	+$2.06K	﹤0.01%	807

Other funds holding HUMA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Howe & Rusling's HUMA Position: Q2 2022 in Review

Howe & Rusling sold out of Humacyte (HUMA) in Q2 2022, closing a stake of 200 shares — an estimated $1K sold.

Howe & Rusling first reported a position in HUMA in Q2 2021 and held it in 4 quarters. The position peaked at $2K in Q3 2021. 78 funds tracked by Wall St. Rank hold HUMA as of Q2 2022.

Howe & Rusling reported no remaining Humacyte position as of Q2 2022 after selling out during the quarter.
Howe & Rusling sold 200 Humacyte shares in Q2 2022, an estimated $1K.
Howe & Rusling first reported a position in Humacyte in Q2 2021 and held it in 4 quarters.
Howe & Rusling's Humacyte position peaked at $2K in Q3 2021.
78 funds tracked by Wall St. Rank held Humacyte as of Q2 2022.

Based on Howe & Rusling's 13F filing for Q2 2022, filed 15 Aug 2022.